What is Bioconvergence Investing?

Bioconvergence isn’t a sector; it’s an entirely new investing paradigm. Genoa Ventures sits at the collision of biology and technology, backing science-driven companies of consequence that don’t fit conventional VC boxes but will define the next generation of markets. Innovation in biology is moving faster than the investment community’s traditional methods.

Genoa Ventures recognizes that we have entered the era of Bioconvergence - a powerful collision where disciplines merge to solve problems once thought unsolvable. This shift requires more than just capital; it demands a fundamental rethink of how we identify and support the companies that are building and defining entirely new categories. In this video, Jenny Rooke and the Genoa team explore why the most significant opportunities of our time live in the spaces between traditional sectors. From Attune Neurosciences’ breakthrough in non-invasive deep-brain stimulation to Bond Pet Foods’ mastery of precision fermentation, we are seeing a new spectrum of solutions that treat biology as the ultimate technology.

As we gain the tools to understand and engineer life at the molecular and atomic levels, the boundaries of what is possible are expanding. This is an invitation to look past the conventional landscape and discover the transformative potential of the bioconvergence frontier.

Conviction in Complexity

Finding conviction in complex science is not about moving faster. It is about going deeper.

In Finding Conviction in Complexity, members from Genoa Ventures explain how they build confidence in scientific and commercial ideas that most investors struggle to evaluate. These are companies operating at the edge of what is known, where both the technology and the business model are still taking shape.

Genoa works alongside founders for months and sometimes years, studying the science, shaping strategy, and testing assumptions before capital is committed. This long view allows risk to be addressed early and partnerships to form before the pressure of scale begins.

In this video, Jenny Rooke, Managing Director and Vikram Chaudhery, Partner share why the most important work happens before an investment is made. Founders from Alida Biosciences, Codetta Bio, SimBioSys, Meiogenix, and Aqtual describe what it means to work with an investor that takes the time to truly understand complex technology and help turn it into clear direction.

After investment, that understanding carries into the boardroom, where Genoa stays closely involved in decision-making as companies grow. This is a look at how conviction in difficult science is built through time, technical insight, and close collaboration with founders.

First Quarter of the Century of Human Genomics

In this video, Jenny Rooke, PhD, Founder and Managing Director of Genoa Ventures, traces the extraordinary evolution of human genomics over the past 25 years, and where it is heading next. She explains how the completion of the Human Genome Project in 2000 marked a defining milestone, but also only the beginning of a rapidly scaling information science powered by automation, computation, and AI.

Dr. Rooke explores the next frontier, moving beyond simply reading DNA. With tools like CRISPR enabling precise genome editing and emerging ideas around using biological systems as programmable environments, biology is starting to resemble an information system more than a traditional life science.

She also highlights a less obvious layer of biological communication, suggesting that vast untapped information may be circulating between cells. Despite these advances, she emphasizes that we are still in the earliest stages of learning to truly program biology.

Frontier to Fundable

“Frontier to Fundable” showcases founders from Genoa Ventures' portfolio as they discuss building “category-defying” businesses at the intersection of biology and technology. Many of today’s most important innovations don’t fit traditional industry labels, which makes them harder to fund and scale. The team at Genoa Ventures has a deep understanding of these emerging areas, supports founders working on highly technical science-driven companies, and helps build the frameworks needed for entirely new markets.

Across the founder stories, there’s a shared theme: they are creating breakthrough technologies in areas like sustainable food, neurotechnology, and precision fermentation, often by rethinking how biology can be engineered or applied. These companies have all faced skepticism because their products don’t resemble existing categories, but

Genoa Ventures exists to back ambitious scientific founders early as they build the next generation of industries.